Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed Primary CNS Lymphoma
NCT07839247Phase 2
Key facts
- Status
- Recruiting
- Start
- Sep 2026
- Primary completion
- Oct 2027
- Countries
- 1
- Conditions
- primary central nervous system lymphoma (PCNSL)
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and lenalidomide in primary central nervous system lymphoma (PCNSL). Primary endpoint: Complete Response Rate at 3 months. Started Sep 2026; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Zanubrutinib plus lenalidomide
Zanubrutinib 160 mg twice daily + Lenalidomide 25 mg once daily (days 1-21 of 28-day cycle)
03
Who it enrols
Frail elderly patients (>= 70 years) with newly diagnosed primary CNS lymphoma, ECOG 0-3, adequate organ function, and no active infections or significant cardiovascular disease.
04
Endpoints
Primary
Complete Response Rate
Secondary
Complete Response Rate
Overall Response Rate
Progression-Free Survival
Duration of Response
Overall Survival
Adverse Events
Serious Adverse Events
Beyond the preview
Go deeper on NCT07839247.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07839247.